Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 4.320

+0.2%

Oct 4 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tktrimbath	12/30/2022 4:57:38 PM
	of 3566

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too. Geron GERN (market cap is $0.922B was $0.585B) Geron is a leading-edge biotech aimed at treating blood disorders by using innovative telomerase techniques. Telomeres are the end caps to chromosome that regulate cell division and cell death. Too aggressive cell death can be associated with autoimmune diseases. Too aggressive cell division can be cancerous. Control cell division and cell death and it may be possible to treat more than their target disorder, thereby multiplying the treatments' and the company's impact. The company has been working on developing a commercially viable treatment for over twenty years and may finally be within a year or two of applying for FDA approval. That's the good news. (Mostly a copy&paste for my biotech investments with the names changed) One hurdle with biotechs is making sure the treatment is reliable, effective, safe, and commercially viable. Another hurdle with innovative treatments is gaining FDA approval is a reasonable time. Treatments for unmet needs have pressure for early approval. Innovative treatments have pressures encouraging the FDA to be cautious. We may soon see how the technical, political, medical, and societal pressures affect Geron's treatment and Geron's viability and GERN's performance. DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals. (I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net & from my One Company One Story series on YouTube youtu.be )

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next